Letter | Published:

Trifluoromethylation of arenes and heteroarenes by means of photoredox catalysis

Nature volume 480, pages 224228 (08 December 2011) | Download Citation

Abstract

Modern drug discovery relies on the continual development of synthetic methodology to address the many challenges associated with the design of new pharmaceutical agents1. One such challenge arises from the enzymatic metabolism of drugs in vivo by cytochrome P450 oxidases, which use single-electron oxidative mechanisms to rapidly modify small molecules to facilitate their excretion2. A commonly used synthetic strategy to protect against in vivo metabolism involves the incorporation of electron-withdrawing functionality, such as the trifluoromethyl (CF3) group, into drug candidates3. The CF3 group enjoys a privileged role in the realm of medicinal chemistry because its incorporation into small molecules often enhances efficacy by promoting electrostatic interactions with targets, improving cellular membrane permeability, and increasing robustness towards oxidative metabolism of the drug4,5,6. Although common pharmacophores often bear CF3 motifs in an aromatic system, access to such analogues typically requires the incorporation of the CF3 group, or a surrogate moiety, at the start of a multi-step synthetic sequence. Here we report a mild, operationally simple strategy for the direct trifluoromethylation of unactivated arenes and heteroarenes through a radical-mediated mechanism using commercial photocatalysts and a household light bulb. We demonstrate the broad utility of this transformation through addition of CF3 to a number of heteroaromatic and aromatic systems. The benefit to medicinal chemistry and applicability to late-stage drug development is also shown through examples of the direct trifluoromethylation of widely prescribed pharmaceutical agents.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , eds. Modern Drug Synthesis (Wiley, 2010)

  2. 2.

    , ed. Cytochrome P450: Structure, Mechanism, and Biochemistry (Springer, 2005)

  3. 3.

    , , , eds. Organofluorine Compounds in Medicinal Chemistry and Biomedical Applications (Elsevier, 1993)

  4. 4.

    , & Fluorine in pharmaceuticals: looking beyond intuition. Science 317, 1881–1886 (2007)

  5. 5.

    , , & Fluorine in medicinal chemistry. Chem. Soc. Rev. 37, 320–330 (2008)

  6. 6.

    The many roles for fluorine in medicinal chemistry. J. Med. Chem. 51, 4359–4369 (2008)

  7. 7.

    & Aromatic trifluoromethylation with metal complexes. Chem. Rev. 111, 4475–4521 (2011)

  8. 8.

    , & Catalysis for fluorination and trifluoromethylation. Nature 473, 470–477 (2011)

  9. 9.

    , & Aromatic trifluoromethylation catalytic in copper. Chem. Commun. 1909–1911 (2009)

  10. 10.

    et al. The palladium-catalyzed trifluoromethylation of aryl chlorides. Science 328, 1679–1681 (2010)

  11. 11.

    , & Pd (II)-catalyzed ortho-trifluoromethylation of arenes using TFA as a promoter. J. Am. Chem. Soc. 132, 3648–3649 (2010)

  12. 12.

    et al. Copper-catalyzed trifluoromethylation of aryl boronic acids using a CF3+ reagent. Chem. Commun. 47, 4300–4302 (2011)

  13. 13.

    & Merging photoredox catalysis with organocatalysis: the direct asymmetric alkylation of aldehydes. Science 322, 77–80 (2008)

  14. 14.

    , & Visible light photocatalysis as a greener approach to photochemical synthesis. Nature Chem. 2, 527–532 (2010)

  15. 15.

    & Visible light photoredox catalysis: applications in organic synthesis. Chem. Soc. Rev. 40, 102–113 (2011)

  16. 16.

    et al. Ru(II) polypyridine complexes: photophysics, photochemistry, electrochemistry, and chemiluminescence. Coord. Chem. Rev. 84, 85–277 (1988)

  17. 17.

    , & Enantioselective α-trifluoromethylation of aldehydes via photoredox organocatalysis. J. Am. Chem. Soc. 131, 10875–10877 (2009)

  18. 18.

    , , , & Outer-sphere dissociative electron transfer to organic molecules: a source of radicals or carbanions? Direct and indirect electrochemistry of perfluoroalkyl bromides and iodides. J. Am. Chem. Soc. 112, 3509–3520 (1990)

  19. 19.

    et al. Luminescent metal complexes. Part 3. Electrochemical potentials of ground and excited states of ring-substituted 2,2’-bipyridyl and 1,10-phenanthroline tris-complexes of ruthenium. J. Chem. Soc. Perkin Trans. 2 1309–1311 (1984)

  20. 20.

    , & Predicting the reactivity of fluorinated compounds with copper using semi-empirical calculations. J. Fluor. Chem. 107, 1–3 (2001)

  21. 21.

    & Introduction of perfluoroalkyl groups — a new approach. J. Fluor. Chem. 45, 86 (1989)

  22. 22.

    , & Reactions of perfluoroalkanesulfonyl chlorides with aromatic compounds catalyzed by a ruthenium (II) complex. Chem. Lett. 19, 649–650 (1990)

  23. 23.

    , , , & Direct perfluoroalkylation of aromatic and heteroaromatic compounds with perfluoroalkanesulfonyl chlorides catalysed by a ruthenium(II) phosphine complex. J. Chem. Soc. Perkin Trans. 1 1339–1346 (1994)

  24. 24.

    Fluorinated free radicals. Top. Curr. Chem. 192, 97–163 (1997)

  25. 25.

    , & Trifluoromethylation of aromatic compounds with sodium trifluoromethanesulfinate under oxidative conditions. Tetrahedron Lett. 32, 7525–7528 (1991)

  26. 26.

    , & Electrophilic trifluoromethylation of arenes and N-heteroarenes using hypervalent iodine reagents. J. Fluor. Chem. 131, 951–957 (2010)

  27. 27.

    & Oxidation of hydroxycyclohexadienyl radical by metal ions. J. Phys. Chem. 78, 2335–2338 (1974)

  28. 28.

    , , , & The clinical pharmacology of 5-trifluoromethyl-2'-deoxyuridine. Cancer Res. 32, 247–253 (1972)

  29. 29.

    The discovery and development of atorvastatin, a potent novel hypolipidemic agent. Prog. Med. Chem. 40, 1–22 (2002)

  30. 30.

    et al. Innate C–H trifluoromethylation of heterocycles. Proc. Natl Acad. Sci. USA 108, 14411–14415 (2011)

Download references

Acknowledgements

Financial support was provided by the NIH General Medical Sciences (R01 01 GM093213-01) and gifts from Merck, Amgen, Abbott and Bristol-Myers Squibb. We thank C. Kraml and N. Byrne of Lotus Separations LLC for their development of preparatory supercritical fluid chromatography (SFC) methods and for the separation of all three CF3-Lipitor analogues.

Author information

Affiliations

  1. Merck Center for Catalysis at Princeton University, Department of Chemistry, 192 Frick Laboratory, Princeton, New Jersey 08540, USA

    • David A. Nagib
    •  & David W. C. MacMillan

Authors

  1. Search for David A. Nagib in:

  2. Search for David W. C. MacMillan in:

Contributions

D.A.N. performed and analysed experiments. D.A.N. and D.W.C.M. designed experiments to develop this reaction and probe its utility, and also prepared this manuscript. Correspondence and requests for materials should be addressed to D.W.C.M. (dmacmill@princeton.edu).

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to David W. C. MacMillan.

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    This file contains Supplementary Text and Data including Supplementary Figures 1-2 (sections 1-5) and NMR Spectra (section 6) - see contents for details.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nature10647

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.